Granules India Buyback – Ray Of Hope During Coronavirus Turmoil?
Q4 Impacted By Export Restrictions
Executive Summary
Granules India’s buyback offer seems to be timed right. As the novel coronavirus crisis batters the Indian stock market, a 32% premium offered by the company is an attractive proposition for investors. However, its Q4 performance will see a blip on account of paracetamol export restrictions.
You may also be interested in...
Fosun’s IPO Plan For India’s Gland Hits Multiple Targets
With a proposed IPO, Gland Pharma’s parent company, Fosun Pharma, hopes to raise funds for its injectables business and possibly its COVID-19 vaccine. The move will also cut Chinese ownership against a backdrop of shaky relations between India and China. As investors warm up to pharma stocks, the timing seems right.
Granules India Next On PE Buy List?
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for PE funds.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip